Peregrine Asset Advisers’s Gilead Sciences GILD Stock Holding History

Peregrine Asset Advisers’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,300	Closed	-$312K	–	125
2021 Q4	$312K	Hold	4,300	–	–	0.13%	97
2021 Q3	$300K	Buy	+4,300	New	+$302K	0.15%	93
2020 Q2	–	Sell	-3,600	Closed	-$269K	–	116
2020 Q1	$269K	Buy	+3,600	New	+$249K	0.2%	67
2016 Q2	–	Sell	-3,051	Closed	-$280K	–	113
2016 Q1	$280K	Buy	+3,051	New	+$275K	0.21%	80
2015 Q4	–	Sell	-10,210	Closed	-$5.13M	–	95
2015 Q3	$5.13M	Sell	10,210 -12,777	-56%	-$1.42M	5.23%	5
2015 Q2	$2.69M	Buy	22,987 +13	+0.1%	+$1.42K	2.02%	19
2015 Q1	$2.25M	Sell	22,974 -11,813	-34%	-$1.2M	1.48%	20
2014 Q4	$3.28M	Sell	34,787 -10,722	-24%	-$1.11M	2.31%	13
2014 Q3	$4.84M	Buy	45,509 +37,590	+475%	+$3.68M	3.98%	1
2014 Q2	$657K	Buy	7,919 +1,850	+30%	+$144K	0.59%	47
2014 Q1	$430K	Buy	+6,069	New	+$476K	0.33%	65

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Peregrine Asset Advisers's GILD Position: Q1 2022 in Review

Peregrine Asset Advisers sold out of Gilead Sciences (GILD) in Q1 2022, closing a stake of 4,300 shares — an estimated $312K sold.

Peregrine Asset Advisers first reported a position in GILD in Q1 2014 and held it in 11 quarters. The position peaked at $5.13M in Q3 2015. 1,600 funds tracked by Wall St. Rank hold GILD as of Q1 2022.

Peregrine Asset Advisers reported no remaining Gilead Sciences position as of Q1 2022 after selling out during the quarter.
Peregrine Asset Advisers sold 4,300 Gilead Sciences shares in Q1 2022, an estimated $312K.
Peregrine Asset Advisers first reported a position in Gilead Sciences in Q1 2014 and held it in 11 quarters.
Peregrine Asset Advisers's Gilead Sciences position peaked at $5.13M in Q3 2015.
1,600 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2022.

Based on Peregrine Asset Advisers's 13F filing for Q1 2022, filed 5 May 2022.